These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 17985712)

  • 1. [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions].
    Persson U; Ramsberg J
    Lakartidningen; 2007 Oct 17-23; 104(42):3046-50. PubMed ID: 17985712
    [No Abstract]   [Full Text] [Related]  

  • 2. [Discount for only one drug of the same group leads to impaired health care quality].
    Bergström R
    Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
    [No Abstract]   [Full Text] [Related]  

  • 3. [Guidelines of the Pharmaceutical Benefits Board for health economics evaluations. Cost-efficiency analysis from a national perspective].
    Lundin D; Carlsson P; Levin LA; Persson U
    Lakartidningen; 2006 Nov 22-28; 103(47):3716-8. PubMed ID: 17212321
    [No Abstract]   [Full Text] [Related]  

  • 4. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
    Anell A; Persson U
    Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
    Langley PC
    Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
    Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The strategic interaction between firms and formulary committees: effects on the prices of new drugs.
    García-Alonso MD; García-Mariñoso B
    J Health Econ; 2008 Mar; 27(2):377-404. PubMed ID: 18276026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AWP reimbursement scrutinized by several states.
    Carroll J
    Manag Care; 2003 Apr; 12(4):11-2. PubMed ID: 12747021
    [No Abstract]   [Full Text] [Related]  

  • 11. [Choice of drugs--by whom, for whom and to what costs?].
    Frisk M; Strömstedt A
    Lakartidningen; 2000 Sep; 97(39):4343-6. PubMed ID: 11076479
    [No Abstract]   [Full Text] [Related]  

  • 12. A call for fairness in formulary decisions.
    Levinson W; Laupacis A
    Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806
    [No Abstract]   [Full Text] [Related]  

  • 13. [Policies concerning pharmaceutical prices and reimbursement in Mexico, Organization for Co-operation and Economic Development. 2007].
    Moïse P; Docteur E
    Salud Publica Mex; 2008; 50 Suppl 4():S504-10. PubMed ID: 19082262
    [No Abstract]   [Full Text] [Related]  

  • 14. [Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations].
    Postma MJ; Kwik JJ; Rutten WJ; de Jong-van den Berg LT; Brouwers JR
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1082-7. PubMed ID: 12085558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Grice S
    N Z Bioeth J; 2003 Oct; 4(3):22-4. PubMed ID: 15597479
    [No Abstract]   [Full Text] [Related]  

  • 16. Economics of biological therapies.
    Kelly CJ; Mir FA
    BMJ; 2009 Aug; 339():b3276. PubMed ID: 19700510
    [No Abstract]   [Full Text] [Related]  

  • 17. [Health economic evaluation of recommended drug treatment].
    Jendteg S; Persson U; Anell A
    Lakartidningen; 2002 Jul; 99(30-31):3130-1. PubMed ID: 12198934
    [No Abstract]   [Full Text] [Related]  

  • 18. On macroeconomic characteristics of pharmaceutical generics and the potential for manufacturing and consumption under fuzzy conditions.
    Gascón F; de la Fuente D; Puente J; Lozano J
    Artif Intell Med; 2007 Nov; 41(3):223-35. PubMed ID: 17719212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Menkes DB; Woodall AA
    N Z Bioeth J; 2003 Oct; 4(3):22, 24-5. PubMed ID: 15597480
    [No Abstract]   [Full Text] [Related]  

  • 20. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Woolner D
    N Z Bioeth J; 2003 Oct; 4(3):22, 25-6. PubMed ID: 15597481
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.